Researcher.Life Logo

Advances in Therapy : Impact Factor & More

eISSN: 1865-8652pISSN: 0741-238X

Aims and Scope of Advances in Therapy

Advances in Therapy is a monthly peer-reviewed medical journal covering clinical medicine, especially research on pharmaceuticals. The Managing Editor is Clare Shepherd. The journal publishes original clinical research papers and review articles. The journal was established in 1984 and published by Health Communications. Since 2008 it has been published by Springer Science+Business Media. Less

Key Metrics

CiteScore
5
Eigenfactor
0.005 - 0.01
H-Index
74
Impact Factor
< 5
Scite Index
0.88 5-Year SI
SJR
Q1Pharmacology (medical)
SNIP
1.37
Recommended pre-submission checks
Powered by Paperpal by Editage

Topics Covered on Advances in Therapy

Advances in Therapy Journal Specifications

Indexed in the following public directories

  • Web of Science Web of Science
  • Scopus Scopus
  • SJR SJR
Overview
Publisher SPRINGER
Language English
Frequency Monthly
General Details
LanguageEnglish
FrequencyMonthly
Publication Start Year1984
Publisher URLVisit website
Website URLVisit website
View less

Planning to publish in Advances in Therapy ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in Advances in Therapy

Real-World Risk of Myelodysplastic Syndrome/Acute Myeloid Leukemia and Other Second Primary Malignancies in Patients with Epithelial Ovarian Cancer Treated with Niraparib Maintenance Therapy: Results from a Postauthorization Safety Study.
  • 20 May 2026
  • Advances in therapy
Moderate and Severe Exacerbations and Healthcare Resource Utilization in Chinese Patients with COPD on Triple Therapy: A Retrospective Database Study.
  • 20 May 2026
  • Advances in therapy
Safety and Effectiveness of Guanfacine Hydrochloride Extended-Release in Adult Patients with ADHD in Japan: A Post-Marketing Surveillance Study.
  • 20 May 2026
  • Advances in therapy
Post Hoc Analysis of Recombinant C1 Inhibitor Clinical Data Using Contemporary Endpoints for Hereditary Angioedema.
  • 20 May 2026
  • Advances in therapy
A Phase IV, Randomized, Double-Blind, Crossover Study to Compare the Clinical Safety and Efficacy of AbobotulinumtoxinA and OnabotulinumtoxinA in Adult Upper Limb Spasticity.
  • 20 May 2026
  • Advances in therapy
Efficacy and Safety of Firsekibart in Patients with Acute Gout Unsuitable for Standard Therapy: 48-Week Results from an Open-Label Extension of a Randomized Phase 3 Trial.
  • 19 May 2026
  • Advances in therapy
Real-World Risk of Myelodysplastic Syndrome/Acute Myeloid Leukemia and Other Second Primary Malignancies in Patients with Epithelial Ovarian Cancer Treated with Niraparib Maintenance Therapy: Results from a Postauthorization Safety Study.
  • 20 May 2026
  • Advances in therapy
Moderate and Severe Exacerbations and Healthcare Resource Utilization in Chinese Patients with COPD on Triple Therapy: A Retrospective Database Study.
  • 20 May 2026
  • Advances in therapy
Safety and Effectiveness of Guanfacine Hydrochloride Extended-Release in Adult Patients with ADHD in Japan: A Post-Marketing Surveillance Study.
  • 20 May 2026
  • Advances in therapy
Post Hoc Analysis of Recombinant C1 Inhibitor Clinical Data Using Contemporary Endpoints for Hereditary Angioedema.
  • 20 May 2026
  • Advances in therapy
A Phase IV, Randomized, Double-Blind, Crossover Study to Compare the Clinical Safety and Efficacy of AbobotulinumtoxinA and OnabotulinumtoxinA in Adult Upper Limb Spasticity.
  • 20 May 2026
  • Advances in therapy
Efficacy and Safety of Firsekibart in Patients with Acute Gout Unsuitable for Standard Therapy: 48-Week Results from an Open-Label Extension of a Randomized Phase 3 Trial.
  • 19 May 2026
  • Advances in therapy

FAQs on Advances in Therapy